N. Sato

发表

Development of a selective and potent radioactive ligand for histamine H(3) receptors: A compound potentially useful for receptor occupancy studies.

Y. Mitobe, Sayaka Ito, Takashi Mizutani, 2009, Bioorganic & medicinal chemistry letters.

Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.

R. Yoshimoto, Y. Mitobe, Sayaka Ito, 2009, Bioorganic & medicinal chemistry letters.

Development of novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.

Sayaka Ito, Takashi Mizutani, T. Nagase, 2008, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of a spiro-isobenzofuranone class of histamine H3 receptor inverse agonists.

Sayaka Ito, N. Sato, S. Tokita, 2008, Bioorganic & Medicinal Chemistry Letters.

Discovery of imidazo[1,2-a]pyridines as potent MCH1R antagonists.

H. Iwaasa, S. Sakuraba, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

Discovery of novel phenylpyridone derivatives as potent and selective MCH1R antagonists.

H. Iwaasa, A. Kanatani, Masahiko Ito, 2011, Bioorganic & medicinal chemistry.

Design and synthesis of the potent, orally available, brain-penetrable arylpyrazole class of neuropeptide Y5 receptor antagonists.

M. Hirose, N. Fujino, A. Kanatani, 2003, Journal of medicinal chemistry.

Synthesis, characterization, and monkey positron emission tomography (PET) studies of [18F]Y1-973, a PET tracer for the neuropeptide Y Y1 receptor

Hisashi Ohta, Mangay Williams, Richard Hargreaves, 2011, NeuroImage.

Synthesis and evaluation of a series of 2,4-diaminopyridine derivatives as potential positron emission tomography tracers for neuropeptide Y Y1 receptors.

Tomoki Suzuki, M. Kameda, M. Ando, 2009, Bioorganic & medicinal chemistry letters.

Facile one-pot synthesis of N-difluoromethyl-2-pyridone derivatives.

M. Ando, N. Sato, Toshihiro Wada, 2006, Organic letters.

Hemodynamic and Cardiac Neurotransmitter-releasing Effects in Conscious Dogs of Attention- and Wake-promoting Agents: A Comparison of d-Amphetamine, Atomoxetine, Modafinil, and a Novel Quinazolinone H3 Inverse Agonist

J. Renger, P. Tannenbaum, C. Regan, 2009, Journal of cardiovascular pharmacology.

Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.

H. Iwaasa, M. Ando, T. Ohe, 2009, Journal of medicinal chemistry.

Total synthesis of octalactin A via ring-closing metathesis reaction

N. Sato, K. Buszek, Youngmee Jeong, 2002 .

Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.

R. Yoshimoto, T. Fukami, Y. Mitobe, 2008, Journal of medicinal chemistry.

Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.

H. Iwaasa, H. Matsushita, M. Ando, 2009, Bioorganic & medicinal chemistry.

A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice.

D. Macneil, H. Iwaasa, L. V. D. van der Ploeg, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Discovery of novel benzoxazinones as potent and orally active long chain fatty acid elongase 6 inhibitors.

R. Yoshimoto, Takashi Mizutani, T. Nagase, 2009, Journal of medicinal chemistry.

FACILE SYNTHESIS OF SATURATED EIGHT-MEMBERED RING LACTONES

N. Sato, K. Buszek, P. L. Muiño, 2001 .

Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists.

H. Iwaasa, M. Ando, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

(9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist.

H. Iwaasa, M. Ando, T. Ohe, 2008, Journal of medicinal chemistry.

Synthesis and evaluation of a novel indoledione class of long chain fatty acid elongase 6 (ELOVL6) inhibitors.

R. Yoshimoto, T. Nagase, N. Sato, 2009, Journal of medicinal chemistry.

Total Synthesis of Octalactin A and B

N. Sato, K. Buszek, Youngmee Jeong, 1994 .

Synthesis and biological evaluation of a novel 3-sulfonyl-8-azabicyclo[3.2.1]octane class of long chain fatty acid elongase 6 (ELOVL6) inhibitors.

R. Yoshimoto, T. Nagase, N. Sato, 2009, Journal of medicinal chemistry.

Discovery of novel spiro-piperidine derivatives as highly potent and selective melanin-concentrating hormone 1 receptor antagonists.

H. Iwaasa, M. Ishikawa, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

Modulation of neuropeptide Y receptors for the treatment of obesity

M. Ando, Y. Ogino, N. Sato, 2009, Expert opinion on therapeutic patents.

Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.

Shigeru Tokita, Shiho Ishikawa, Akane Ishihara, 2008, Journal of medicinal chemistry.

Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6.

R. Yoshimoto, T. Ohe, T. Nagase, 2010, European journal of pharmacology.

Identification and characterization of a selective radioligand for ELOVL6.

D. Dean, Cheng Tang, T. Nagase, 2009, Journal of biochemistry.

Synthesis and evaluation of a novel 2-azabicyclo[2.2.2]octane class of long chain fatty acid elongase 6 (ELOVL6) inhibitors.

R. Yoshimoto, T. Nagase, N. Sato, 2009, Bioorganic & medicinal chemistry.

5,5-Dimethyl-3-(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione, a Potent Inhibitor for Mammalian Elongase of Long-Chain Fatty Acids Family 6: Examination of Its Potential Utility as a Pharmacological Tool

R. Yoshimoto, T. Ohe, T. Nagase, 2009, Journal of Pharmacology and Experimental Therapeutics.

Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists.

Kouta Masutani, M. Kameda, H. Matsushita, 2009, Bioorganic & medicinal chemistry letters.

Identification and characterization of a selective radioligand for melanin-concentrating hormone 1-receptor (MCH1R).

H. Iwaasa, H. Matsushita, D. Dean, 2009, Bioorganic & medicinal chemistry letters.

Novel potent neuropeptide Y Y5 receptor antagonists: synthesis and structure-activity relationships of phenylpiperazine derivatives.

H. Iwaasa, M. Hirose, A. Kanatani, 2006, Bioorganic & medicinal chemistry.

Identification of 2-[2-(4-tert-Butylphenyl)ethyl]-N-[4-(3-cyclopentylpropyl)-2-fluorophenyl]-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide as an Orally Active MGAT2 Inhibitor.

F. Io, Akiko Nozoe, N. Sato, 2016, Chemical & pharmaceutical bulletin.

Identification of 2-[2-(4-tert-butylphenyl)ethyl]-N-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide (29) as an orally available MGAT2 inhibitor.

N. Sato, E. Munetomo, K. Kitano, 2015, Bioorganic & medicinal chemistry.

Melanin-concentrating hormone 1-receptor antagonist suppresses body weight gain correlated with high receptor occupancy levels in diet-induced obesity mice.

D. Macneil, H. Iwaasa, H. Matsushita, 2009, European journal of pharmacology.

Histamine H3 inverse agonist PET tracers labelled with carbon-11 or fluorine-18

S. Doran, L. Gantert, J. Renger, 2008, NeuroImage.

Inverse agonist histamine H3 receptor PET tracers labelled with carbon‐11 or fluorine‐18

Christine Ryan, Richard Hargreaves, Shigeru Tokita, 2009, Synapse.

Modulation of neuropeptide Y receptors for the treatment of obesity

M. Ando, Y. Ogino, N. Sato, 2009, Expert opinion on therapeutic patents.

Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.

Tomoki Suzuki, M. Kameda, M. Ando, 2009, Bioorganic & medicinal chemistry letters.

H. Iwaasa, M. Ando, T. Ohe, 2009, Journal of medicinal chemistry.

Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.

R. Yoshimoto, T. Fukami, Sayaka Ito, 2008, Journal of medicinal chemistry.

J. Renger, P. Tannenbaum, C. Regan, 2009, Journal of Cardiovascular Pharmacology.

Mechanism of the anti‐obesity effects induced by a novel Melanin‐concentrating hormone 1‐receptor antagonist in mice

D. Macneil, H. Iwaasa, A. Kanatani, 2010, British journal of pharmacology.

Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists.

Tomoki Suzuki, M. Ando, Kensuke Kobayashi, 2009, Bioorganic & medicinal chemistry letters.